

*HemoSavin Pharma*

*The First Oral Small  
Molecule Hemophilia A  
Treatment*



*HemoSavin Pharmaceuticals (US) Inc. is a preclinical stage company focused on the commercialization of The First Oral Small Molecule Treatment for Hemophilia A.*

Fort Collins, Colorado, US [mgore@yewsavin.com](mailto:mgore@yewsavin.com) +1 541 740 6226  
**[www.hemosavin.com](http://www.hemosavin.com)**

## Key Advantages:

- Innovative Oral Therapy: Our small molecule is the first affordable oral treatment for Hemophilia A, eliminating the need for frequent injections with a **simple daily pill**.
- Superior Safety Profile: Initial safety testing demonstrates **no adverse effects**, which is critical for patient well-being.
- Clinically Significant Reduction in Blood Loss: Clinical studies by **oral administration** in HA mice reveal a remarkable 70% reduction in blood loss.
- Competitive Cost: The cost of manufacturing small molecules is potentially significantly lower than that of injectables. Hemosavin therapy offers a **cost-effective treatment** without compromising efficacy.



## Team:

The Core and Advisory Team Has Expertise Across the Entire Development Roadmap



**Dr. Mak Gore**  
President/CTO



**Ashay Gore**  
Science Officer



**Dr. Steven Pipe**  
UM Advisor



**Dr. Suresh Yeola**  
Preclinical



**Dr. Sarath Kanekal**  
FDA/Clinical



**Rajeshwari (Raj)**  
VP Business  
Development

# Scientific Validation:

Significant Improvement in Clotting Parameters for: Hemophilia A (HA) Mouse, Human plasma, HA Dog Plasma and ex-vivo Human Blood Studies

## Key Findings:

Clinically Significant 70% blood loss reduction in HA Mice by oral administration at 6mg/mouse and in FOUR different coagulation tests



## Preclinical Test Results:

Hemophilia A  
Mouse Oral  
in-vivo :  
Tail-clip



Reduction in  
Blood Loss

Hemophilia A  
Human  
Plasma:  
In vitro



Reduction in  
Clotting Time  
(aPTT)

Hemophilia A  
Canine  
Plasma:  
In vitro



Reduction in  
Clotting Time  
(aPTT)

Hemophilia A  
Human Blood:  
Ex-vivo  
Human Patient



Decrease in  
whole blood  
coagulation  
time



## Competitive Analysis:

This is therapy class in by itself, non-factor, nor a biologic, and not a protein, with effects comparable to current therapy Factor VIII; with advantage of age old pill format **Simple Daily Pill**, an enormous patient advantage over all other competitors ”

## Conclusion:

*We have developed the first oral small molecule therapy for the treatment of hemophilia A, which reduces blood loss in the FVIII-deficient mouse tail bleed assay by 70%, a clinically significant result. Our therapy is orally active in mice at doses as low as 6 mg/mouse, confers a high survival rate, and exhibits good shelf-life stability, ADME properties, and safety profile in preliminary studies. The clinical potential of our therapy is further supported by our observations that it is efficacious in aPTT assays in FVIII-deficient human plasma, ex-vivo human blood, dog plasma, and the thrombin generation assay, showing significant decreases in coagulation times and significant increases in ETP (endogenous thrombin potential).*

Fort Collins, Colorado, US [mgore@yewsavin.com](mailto:mgore@yewsavin.com) +1 541 740 6226

[www.hemosavin.com](http://www.hemosavin.com)